Natural History of Morquio A Syndrome.
New testing approaches could better measure progress in rare metabolic disease patients, helping regulators and doctors evaluate experimental treatments fairly.
This natural history review of Morquio A syndrome (MPS IVA) highlights critical gaps in endpoint validation for clinical trials, as standard endurance tests fail patients with severe phenotypes or postoperative limitations. The authors advocate for non-invasive quantitative multisystem tools and surrogate biochemical biomarkers to enable regulatory-grade endpoints across the full Morquio A phenotypic spectrum.
What the study was
- Study design
- Natural history review
- Population
- Patients with mucopolysaccharidosis IVA (Morquio A, MPS IVA)
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Journal of Inherited Metabolic Disease
Why it surfaced
Rare lysosomal storage disease with high unmet need; review of endpoint gap is directly relevant to pipeline design for future MPS IVA trials.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.